JP2006501292A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501292A5
JP2006501292A5 JP2004540927A JP2004540927A JP2006501292A5 JP 2006501292 A5 JP2006501292 A5 JP 2006501292A5 JP 2004540927 A JP2004540927 A JP 2004540927A JP 2004540927 A JP2004540927 A JP 2004540927A JP 2006501292 A5 JP2006501292 A5 JP 2006501292A5
Authority
JP
Japan
Prior art keywords
alkyl
halogen
substituents
cor
con
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004540927A
Other languages
English (en)
Japanese (ja)
Other versions
JP4653485B2 (ja
JP2006501292A (ja
Filing date
Publication date
Priority claimed from GBGB0223039.9A external-priority patent/GB0223039D0/en
Application filed filed Critical
Publication of JP2006501292A publication Critical patent/JP2006501292A/ja
Publication of JP2006501292A5 publication Critical patent/JP2006501292A5/ja
Application granted granted Critical
Publication of JP4653485B2 publication Critical patent/JP4653485B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004540927A 2002-10-04 2003-09-25 ガンマ−セクレターゼインヒビターとしてのシクロヘキシルスルホン誘導体 Expired - Fee Related JP4653485B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223039.9A GB0223039D0 (en) 2002-10-04 2002-10-04 Therapeutic compounds
PCT/GB2003/004102 WO2004031137A1 (en) 2002-10-04 2003-09-25 Cyclohexyl sulphone derivatives as gamma-secretase inhibitors

Publications (3)

Publication Number Publication Date
JP2006501292A JP2006501292A (ja) 2006-01-12
JP2006501292A5 true JP2006501292A5 (https=) 2010-03-18
JP4653485B2 JP4653485B2 (ja) 2011-03-16

Family

ID=9945313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004540927A Expired - Fee Related JP4653485B2 (ja) 2002-10-04 2003-09-25 ガンマ−セクレターゼインヒビターとしてのシクロヘキシルスルホン誘導体

Country Status (10)

Country Link
US (1) US7101895B2 (https=)
EP (1) EP1551797B1 (https=)
JP (1) JP4653485B2 (https=)
AT (1) ATE354562T1 (https=)
AU (1) AU2003267614B2 (https=)
CA (1) CA2500964C (https=)
DE (1) DE60312016T2 (https=)
ES (1) ES2280774T3 (https=)
GB (1) GB0223039D0 (https=)
WO (1) WO2004031137A1 (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
KR100927304B1 (ko) 2001-12-27 2009-11-18 다이이찌 세이야꾸 가부시기가이샤 β-아밀로이드 단백 생산·분비 저해제
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
PL379466A1 (pl) 2003-06-30 2006-09-18 Daiichi Sankyo Company , Limited Heterocykliczne pochodne metylosulfonu
AR047666A1 (es) * 2004-02-20 2006-02-01 Merck Sharp & Dohme Sintesis estereoselectiva del acido ciclohexanopropanoico 4,4-disubstituido
US20090215775A1 (en) * 2005-05-17 2009-08-27 Huw David Lewis Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
PE20061490A1 (es) * 2005-06-06 2007-02-09 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
GB0513747D0 (en) * 2005-07-06 2005-08-10 Merck Sharp & Dohme Therapeutic compounds
CN102702044A (zh) * 2006-01-20 2012-10-03 先灵公司 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2009008980A2 (en) * 2007-07-05 2009-01-15 Schering Corporation Tetrahydropyranochromene gamma secretase inhibitors
EP2178882B1 (en) 2007-07-17 2013-04-17 Merck Sharp & Dohme Corp. Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
US8377886B2 (en) * 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
AU2009316264B2 (en) 2008-11-24 2016-09-15 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
WO2010090954A1 (en) * 2009-02-06 2010-08-12 Merck Sharp & Dohme Corp. Novel trifluoromethylsulfonamide gamma secretase inhibitor
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
US20150209367A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye & Ear Infirmary Treating Hearing Loss
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
ES2704460T3 (es) * 2014-01-06 2019-03-18 Bristol Myers Squibb Co Moduladores de ROR gamma de ciclohexilsulfona
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
WO2017019496A1 (en) 2015-07-24 2017-02-02 Berenson James Richard Gamma secretase modulators for the treatment of immune system dysfunction
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
EP3407901B1 (en) 2016-01-29 2021-07-21 Massachusetts Eye & Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
JP6840774B2 (ja) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション 肺上皮エンジニアリングにおけるヒト気道幹細胞
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
WO2018111926A2 (en) 2016-12-16 2018-06-21 Inception 3, Inc. Methods of treating cochlear synaptopathy
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US12552826B2 (en) 2018-08-07 2026-02-17 Merck Sharp & Dohme Llc PRMT5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2021126731A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
BR112022012015A2 (pt) 2019-12-17 2022-08-30 Merck Sharp & Dohme Llc Inibidores de prmt5
US12595248B2 (en) 2019-12-17 2026-04-07 Merck Sharp & Dohme Llc PRMT5 inhibitors
CN111205264A (zh) * 2020-02-25 2020-05-29 成都睿智化学研究有限公司 一种合成同位羟基和甲磺酰甲基化合物的新方法
EP4126952A1 (en) 2020-03-26 2023-02-08 Seagen Inc. Methods of treating multiple myeloma
US20240116945A1 (en) 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
GEAP202516798A (en) 2022-12-14 2025-10-27 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802013A (en) 1954-02-12 1957-08-06 Searle & Co 2-(oxo and imino)-3-(phenyl and halophenyl)-tetrahydrofuransulfones and processes for the manufacture thereof
US2812330A (en) 1956-05-02 1957-11-05 Searle & Co Sulfone derivatives of 2, 6-piperidinedione
JPS5625149A (en) 1979-08-08 1981-03-10 Sagami Chem Res Center Keto ester derivative and its preparation
JPS5626847A (en) 1979-08-13 1981-03-16 Sagami Chem Res Center Preparation of substituted salicylic acid derivative
JPS5626866A (en) 1979-08-13 1981-03-16 Sagami Chem Res Center Unsaturated ketoester derivative and its preparation
CA2191924A1 (en) * 1995-12-05 1997-06-06 Kevin Felsenstein 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of .beta.-amyloid protein production
EP0863134A1 (en) 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
WO2001070677A1 (en) * 2000-03-20 2001-09-27 Merck Sharp & Dohme Limited Sulphonamido-substituted bridged bicycloalkyl derivatives
GB0108592D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0108591D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
US7122675B2 (en) * 2001-08-03 2006-10-17 Schering Corporation Gamma secretase inhibitors
JP3711131B2 (ja) 2001-08-21 2005-10-26 メルク シャープ エンド ドーム リミテッド 新規のシクロヘキシルスルホン
KR100927304B1 (ko) 2001-12-27 2009-11-18 다이이찌 세이야꾸 가부시기가이샤 β-아밀로이드 단백 생산·분비 저해제
DE10201392A1 (de) 2002-01-16 2003-07-31 Bayer Ag Phenylsulfoxide und-sulfone
GB0218041D0 (en) 2002-08-02 2002-09-11 Merck Sharp & Dohme Chemical process
JP3092689U (ja) 2002-09-10 2003-03-20 船井電機株式会社 光ピックアップ
GB0223040D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223038D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
DE10254875A1 (de) 2002-11-25 2004-06-03 Bayer Healthcare Ag Phenylsulfoxid und -sulfon-Derivate
GB0304524D0 (en) 2003-02-27 2003-04-02 Merck Sharp & Dohme Therapeutic agents
MXPA05012323A (es) 2003-05-16 2006-01-30 Merck Sharp & Dohme Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
PL379466A1 (pl) 2003-06-30 2006-09-18 Daiichi Sankyo Company , Limited Heterocykliczne pochodne metylosulfonu
GB0323258D0 (en) 2003-10-04 2003-11-05 Merck Sharp & Dohme Therapeutic compounds

Similar Documents

Publication Publication Date Title
JP2006501292A5 (https=)
JP2006501295A5 (https=)
JP2011137006A5 (https=)
JP2005539088A5 (https=)
JP2023539463A5 (https=)
JP2007508359A5 (https=)
JP2005508905A5 (https=)
JP2009515872A5 (https=)
JP2004501905A5 (https=)
JP2003503387A5 (https=)
JP2010528089A5 (https=)
JP2004527498A5 (https=)
JP2002501945A5 (https=)
CA2500964A1 (en) Cyclohexyl sulphone derivatives as gamma-secretase inhibitors
JP2007528417A5 (https=)
JP2008133278A5 (https=)
JP2007511546A5 (https=)
JP2004532266A5 (https=)
JP2005507872A5 (https=)
JP2008074862A5 (https=)
JP2001526258A5 (https=)
JP2006515858A5 (https=)
JP2004521124A5 (https=)
JP2010540525A5 (https=)
JP2009529540A5 (https=)